Harrow, Inc. Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent
Harrow, Inc. (HROW) reported Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent of 1.71% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent · last filed 2026-03-02
- Harrow, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2024 was 1.71%, a 42.42% decline from fiscal 2023.
- Harrow, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2023 was 2.97%, a 1550.00% increase from fiscal 2022.
- Harrow, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2022 was 0.18%, a 92.21% decline from fiscal 2021.
- Harrow, Inc. effective income tax rate reconciliation,other reconciling items, percent for fiscal 2021 was 2.31%.
| Period end | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent 12 month | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | 1.71% 10-K · filed 2026-03-02 | |
| 2023-12-31 | 2.97% 10-K · filed 2026-03-02 | 0.43% 10-K · filed 2024-03-19 |
| 2022-12-31 | 0.18% 10-K · filed 2024-03-19 | 1.98% 10-K · filed 2023-03-23 |
| 2021-12-31 | 2.31% 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |